Donato Martín, Gelpi Ricardo J
Laboratory of Cardiovascular Physiopathology, Department of Pathology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Mol Cell Biochem. 2003 Sep;251(1-2):153-9.
Ischemic heart disease includes a number of entities that have been grouped in accordance with physiopathology and evolutive criteria. In recent years 'new' ischemic syndromes have been described. Within the 'new' ischemic syndromes, ventricular post-ischemic dysfunction--also known as 'stunned myocardium'--is worth mentioning. In this route, several studies have suggested that reperfusion per se could cause cellular injury (reperfusion injury). In previous years, a protective effect on the injury caused by ischemia and reperfusion in the heart has been attributed to adenosine. These effects have been documented in different experimental in vivo and in vitro models. Thus, the administration of exogenous adenosine, or agonists of adenosine receptors prior to ischemia reduces the size of the infarction, improves the recovery of the ventricular function during reperfusion (attenuating stunning) and prolongs the time period to the ischemic contracture. However, focusing on a potential therapeutic application, it is of the utmost importance to find this protection and learn the mechanisms involved when procedures are applied during early reperfusion. We showed that adenosine, administered from the beginning of reperfusion, attenuated systolic and diastolic (myocardial stiffness) alterations of the stunned myocardium. This protective effect was mediated by the activation of A1 adenosine receptors, and without modification on infarct size. According to some authors, adenosine can decrease the release of endothelin, during early reperfusion, and reduce an overload of Ca2+ that could cause a cellular lesion. Finally, ischemic preconditioning involves a series of intracellular events that are initiated with the activation of the A1 receptor, and end at the sensitive K+ ATP channels of the mitochondria. The phosphorylation and opening of these channels would cause the protective effect. Activation of this specific mechanism during reperfusion has not been studied extensively.
缺血性心脏病包括根据病理生理学和演变标准分类的多种病症。近年来,已描述了“新的”缺血综合征。在“新的”缺血综合征中,值得一提的是心室缺血后功能障碍——也称为“心肌顿抑”。在这一过程中,多项研究表明再灌注本身可能导致细胞损伤(再灌注损伤)。前些年,腺苷被认为对心脏缺血和再灌注所致损伤具有保护作用。这些作用已在不同的体内和体外实验模型中得到证实。因此,在缺血前给予外源性腺苷或腺苷受体激动剂可减小梗死面积,改善再灌注期间心室功能的恢复(减轻心肌顿抑),并延长至缺血性挛缩的时间。然而,着眼于潜在的治疗应用,在早期再灌注过程中应用相关措施时,找到这种保护作用并了解其涉及的机制至关重要。我们发现,从再灌注开始时给予腺苷可减轻心肌顿抑的收缩期和舒张期(心肌僵硬度)改变。这种保护作用是由A1腺苷受体的激活介导的,且不改变梗死面积。据一些作者称,腺苷可在早期再灌注期间减少内皮素的释放,并减少可能导致细胞损伤的Ca2+过载。最后,缺血预处理涉及一系列细胞内事件,这些事件始于A1受体的激活,并终止于线粒体的敏感性K+ATP通道。这些通道的磷酸化和开放会产生保护作用。在再灌注期间激活这一特定机制尚未得到广泛研究。